EU consults on future of project for accelerating trials in developing countries
This article was originally published in SRA
The European Commission is seeking feedback on the future of a research and development programme that was set up to accelerate the development of new and improved drugs against HIV/AIDS, malaria and tuberculosis. The programme’s current focus is on conducting Phase II and III clinical trials in Sub-Saharan Africa1,2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.